From research to infrastructure development: Bayer’s commitment to health and social needs
Bayer is active worldwide with various programs to improve health care provision.
For example, Bayer HealthCare for over 30 years has worked to support more than 400,000 hemophilia patients around the world. With medical research, donations and the development of infrastructure, the company improves care for people with hemophilia. Through investment in research and development, Bayer for more than 20 years has compiled extensive data to continuously examine and improve the quality, effectiveness and safety of its biotechnologically manufactured hemophilia medicine Kogenate™. We promote further innovative research approaches with our Bayer Hemophilia Awards Program (BHAP). Since 2002, BHAP has provided total funding of more than US$20 million to 175 projects. In addition, Bayer makes available monetary and product donations to support the World Federation of Hemophilia (WFH), which used the donations to finance various therapy, care and training initiatives. Another program designed to promote optimal patient care is the Bayer European Hemophilia Nurses Scholarship (BEHNS). Through this scholarship program, hemophilia nurses from all over Europe are given the opportunity to gain experience at other hemophilia centers or implement their own scientific projects. Around the world, Bayer supports hemophilia camps for children and young people, such as with a project in Bogor, Indonesia.
One focus of our commitment to better medical care for neglected diseases is Chagas disease. This dangerous infection is widespread in many countries of Central and South America. In our efforts to combat Chagas disease, we are cooperating closely with the World Health Organization (WHO). In addition, our new “Bayer Fights Chagas” project aims to find innovative approaches to controlling this tropical disease. The initiative, which is starting with a pilot project in Argentina, was launched jointly by Bayer HealthCare and the Bayer Cares Foundation. “Bayer Fights Chagas” has a deliberate policy of deploying talented young individuals from various parts of the company and employees from the pilot country WHO volunteer their services. This is the first time that an international team drawn from the various subgroups has sought answers to the question of how Bayer, as a global company, can make a meaningful and lasting contribution to combating Chagas disease.
Our commitment goes beyond improving drug supplies. In line with the declared objective of China’s Ministry of Health to additionally boost medical care in the less developed western part of the country by improving the qualifications of medical staff, our “Go West” project aims to provide physicians from the rural regions of this part of the People’s Republic of China with further training. In cooperation with the Chinese government and local universities, Bayer is organizing continuing education for local physicians to improve diagnosis, treatment and advice for patients. Between 2007 and 2012, some 10,000 physicians from 330 rural districts are to complete three-month training courses in the fields of internal medicine, general surgery, gynecology and obstetrics, laboratory diagnostics and radiology. During the same period, around 600 hospitals are being linked to the leading hospital or clinic in their respective regions. Bayer is making available a total of approximately €2.3 million for “Go West” over this five-year period.